Therapy-related B-lymphoblastic leukemia after multiple myeloma

Swerdlow S.H.C.E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Arber D.A., Hasserjian R.P., Le Beau M.M., Orazi A., Siebert R. WHO classification of tumours of hematopoietic and lymphoid tissues. Revised 4th edition ed. Lyon: IARC; 2017. Voorhees, 2020, Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial, Blood, 136, 936, 10.1182/blood.2020005288 Gribben, 2015, Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma, J. Clin. Oncol., 33, 2803, 10.1200/JCO.2014.59.5363 McCarthy, 2012, Lenalidomide after stem-cell transplantation for multiple myeloma, N. Engl. J. Med., 366, 1770, 10.1056/NEJMoa1114083 Attal, 2012, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma, N. Engl. J. Med., 366, 1782, 10.1056/NEJMoa1114138 Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma, N. Engl. J. Med., 366, 1759, 10.1056/NEJMoa1112704 Dimopoulos, 2012, A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide, Blood, 119, 2764, 10.1182/blood-2011-08-373514 Kazandjian, 2020, The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?, Br. J. Haematol., 191, 692, 10.1111/bjh.16764 Radivoyevitch, 2018, Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma, Leuk. Res., 74, 130, 10.1016/j.leukres.2018.07.016 Parrondo, 2022, Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma, Blood Cancer J., 12, 87, 10.1038/s41408-022-00680-y Ueda, 2009, Early onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma, Ann. Hematol., 88, 813, 10.1007/s00277-008-0680-8 Lau, 2005, Acute lymphoblastic leukemia after tandem autologous stem cell transplantations for multiple myeloma, Leukemia, 19, 299, 10.1038/sj.leu.2403587 Gertz, 2015, Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents, Leuk. Lymphoma, 56, 1723, 10.3109/10428194.2014.970543 Khan, 2018, Acute lymphoblastic leukemia following lenalidomide maintenance for multiple myeloma: two cases with unexpected presentation and good prognostic features, Case Rep. Hematol., 2018 Germans, 2020, Lenalidomide-associated secondary B-lymphoblastic leukemia/lymphoma-A unique entity, Am. J. Clin. Pathol., 154, 816, 10.1093/ajcp/aqaa109 García-Muñoz, 2013, Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma, Leuk. Lymphoma, 54, 2753, 10.3109/10428194.2013.786072 Li, 2016, Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: a case report, Oncol. Lett., 12, 847, 10.3892/ol.2016.4728 Tan, 2017, Lenalidomide and secondary acute lymphoblastic leukemia: a case series, Hematol. Oncol., 35, 130, 10.1002/hon.2248 Tsukada, 2012, [B-cell acute lymphoblastic leukemia developed 5 years after autologous stem cell transplantation for multiple myeloma], Rinsho Ketsueki, 53, 219 Junxun, 2016, Three patients with multiple myeloma developing secondary lymphoblastic leukemia: case reports and review of the literature, Tumori, 102 Gonzalez, 2013, Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma, Ann. Clin. Lab. Sci., 43, 176 Tashakori, 2020, B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma, Blood, 136, 2720, 10.1182/blood.2020009141 Alhuraiji, 2018, Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure, Clin. Case Rep., 6, 155, 10.1002/ccr3.1264 Mei, 2019, Acute B lymphoblastic leukemia developing in patients with multiple myeloma: presentation of two cases, Turk. J. Haematol., 36, 287 Sinit, 2019, B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review, BMC Cancer, 19, 1147, 10.1186/s12885-019-6286-9 Lee, 2019, Two rare cases of therapy-related acute lymphoblastic leukemia in patients with plasma cell myeloma, Ann. Lab. Med., 39, 496, 10.3343/alm.2019.39.5.496 Aldoss, 2019, Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma, Leukemia, 33, 266, 10.1038/s41375-018-0213-y Konishi, 2016, Allogeneic bone marrow transplantation for therapy-related acute lymphocytic leukemia after autologous hematopoietic stem cell transplantation for multiple myeloma, Ann. Hematol., 95, 1739, 10.1007/s00277-016-2762-3 Piszcz, 2012, Secondary acute lymphoblastic leukaemia in a multiple myeloma patient, Contemp. Oncol. (Pozn), 16, 593 Abdel Rahman, 2022, Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia, Br. J. Haematol., 196, 963, 10.1111/bjh.17906 Aldoss, 2017, Philadelphia chromosome as a recurrent event among therapy-related acute leukemia, Am. J. Hematol., 92, E18, 10.1002/ajh.24604 Musto, 2017, Second primary malignancies in multiple myeloma: an overview and IMWG consensus, Ann. Oncol., 28, 228, 10.1093/annonc/mdw606 Zhu, 2007, A novel t(3;19)(p21;p13) in a patient with acute myelocytic leukemia, Cancer Genet. Cytogenet., 179, 165, 10.1016/j.cancergencyto.2007.09.005 Maura, 2021, The mutagenic impact of melphalan in multiple myeloma, Leukemia, 35, 2145, 10.1038/s41375-021-01293-3 Aldoss, 2018, Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients, Haematologica, 103, 1662, 10.3324/haematol.2018.193599 Saygin, 2019, Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes, Blood Adv., 3, 4228, 10.1182/bloodadvances.2019000925 Barnea Slonim, 2021, Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome, Leukemia, 35, 2097, 10.1038/s41375-020-01061-9 Shi, 2022, Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia, Hematology, 27, 642, 10.1080/16078454.2022.2074704